Asahi Kasei acquires Bionova and its shiny new California site
Just months after it opened a new GMP manufacturing site, the US-based biopharma CDMO Bionova Scientific has been acquired by Asahi Kasei Medical.
The company announced the acquisition Monday evening, however, the deal was finalized April 14, the company said.
Bionova specializes in complex next-generation antibody drugs, which can be difficult to manufacture. It launched the full-service commercial-ready GMP manufacturing site in Fremont, CA, just north of San Jose, in October. With the acquisition, Asahi Kasei will get nearly 80,000-square-feet of CDMO facilities and a number of state-of-the-art instruments and equipment, including single-use bioreactors. The acquisition will also allow Asahi Kasei to add a CDMO to its bioprocess business.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters